跳转至内容
Merck
CN
  • Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.

Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.

British journal of pharmacology (2014-07-23)
F Hubert, M Belacel-Ouari, B Manoury, K Zhai, V Domergue-Dupont, P Mateo, F Joubert, R Fischmeister, V Leblais
摘要

This study examined the role of the main vascular cAMP-hydrolysing phosphodiesterases (cAMP-PDE) in the regulation of basal vascular tone and relaxation of rat aorta mediated by β-adrenoceptors, following heart failure (HF). Twenty-two weeks after proximal aortic stenosis, to induce HF, or SHAM surgery in rats, we evaluated the expression, activity and function of cAMP-PDE in the descending thoracic aorta. HF rat aortas exhibited signs of endothelial dysfunction, with alterations of the NO pathway, and alteration of PDE3 and PDE4 subtype expression, without changing total aortic cAMP-hydrolytic activity and PDE1, PDE3 and PDE4 activities. Vascular reactivity experiments using PDE inhibitors showed that PDE3 and PDE4 controlled the level of PGF2α -stimulated contraction in SHAM aorta. PDE3 function was partially inhibited by endothelial NO, whereas PDE4 function required a functional endothelium and was under the negative control of PDE3. In HF, PDE3 function was preserved, but its regulation by endothelial NO was altered. PDE4 function was abolished and restored by PDE3 inhibition. In PGF2α -precontracted arteries, β-adrenoceptor stimulation-induced relaxation in SHAM aorta, which was abolished in the absence of functional endothelium, as well as in HF aortas, but restored after PDE3 inhibition in all unresponsive arteries. Our study underlines the key role of the endothelium in controlling the contribution of smooth muscle PDE to contractile function. In HF, endothelial dysfunction had a major effect on PDE3 function and PDE3 inhibition restored a functional relaxation to β-adrenoceptor stimulation.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
Trizma ® 碱, Primary Standard and Buffer, ≥99.9% (titration), crystalline
Sigma-Aldrich
Trizma ® 碱, BioPerformance Certified, meets EP, USP testing specifications, suitable for cell culture, ≥99.9% (titration)
Sigma-Aldrich
3-异丁基-1-甲基黄嘌呤, ≥99% (HPLC), powder
Sigma-Aldrich
3-异丁基-1-甲基黄嘌呤, BioUltra, ≥99%
Sigma-Aldrich
三(羟甲基)氨基甲烷, ACS reagent, ≥99.8%
Sigma-Aldrich
缓血酸胺, meets USP testing specifications
Sigma-Aldrich
Sigma 7-9®®, ≥99% (titration), powder or crystals
Sigma-Aldrich
Nω-硝基-L-精氨酸甲酯 盐酸盐, ≥97% (TLC), powder
Sigma-Aldrich
Trizma ® 碱, BioUltra, Molecular Biology, ≥99.8% (T)
Sigma-Aldrich
Trizma ® 碱, ≥99.0% (T)
Sigma-Aldrich
Trizma ® 碱, BioXtra, pH 10.5-12.0 (1 M in H2O), ≥99.9% (titration)
Sigma-Aldrich
Trizma ® 碱, ≥99.9% (titration), crystalline
Sigma-Aldrich
Trizma ® 碱, anhydrous, free-flowing, Redi-Dri, ≥99.9%
Sigma-Aldrich
卡巴胆碱, ≥98% (titration), crystalline
Sigma-Aldrich
鸟苷-3′,5′-环一磷酸 钠盐, ≥99% (HPLC), powder
Supelco
缓血酸胺, pharmaceutical secondary standard, certified reference material
Sigma-Aldrich
Trizma ® 碱, 99.7% (T), puriss. p.a.
Sigma-Aldrich
鸟苷 3′,5′-环单磷酸, ≥98% (HPLC), powder
Sigma-Aldrich
Ro-20-1724, A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC₅₀ = 2 µM).
Supelco
Trizma ® 碱, reference material for titrimetry, certified by BAM, >99.5%
USP
缓血酸胺, United States Pharmacopeia (USP) Reference Standard
氨丁三醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
酚妥拉明 盐酸盐, ≥98% (TLC), powder
SAFC
缓血酸胺
Sigma-Aldrich
腺苷-3′,5′-环单磷酸 三羟甲基氨基甲烷盐, ≥97% (HPLC), powder
卡巴胆碱, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Trizma ® 碱, Vetec, reagent grade, ≥99%
Sigma-Aldrich
环己喹酰胺, phosphodiesterase inhibitor